Qvanteq closes series B financing round of CHF4 million

Qvanteq AG is a Zurich, Switzerland, based medtech startup company. Pre-clinical in vivo studies with Qvanteq’s coronary stent have shown a significant reduction of restenosis in comparison to bare metal stents (BMS) and comparable or even better results than what have been observed with drug-eluting stents (DES). In addition, the studies exhibited very fast endothelialization.
 
Qvanteq is therefore positioning its unique bioactive and coating-free coronary stent as a valuable alternative to DES; the observed benefits of its coronary stent potentially increase patient safety while allowing a significant reduction in Dual Anti-Platelet Treatment (DAPT) time.
 
The funds now raised from private investors will be used to obtain clinical proof of concept in a “First-in-Man” study as well as CE market approval for Qvanteq’s stent device.
 
Qvanteq expects a straightforward market approval process, as its groundbreaking surface technology does not involve a coating or elution of any active substance, such as the release of a drug into the patient’s blood stream. Its coating-free surface technology will additionally overcome all of the problems associated with the coating technologies which are currently being applied.
 
Qvanteq was founded in 2009 as a spin-off from the Swiss Federal Institute of Technology (ETH). The company has developed a novel and groundbreaking surface technology that can be applied onto any coronary stent. In 2012 Qvanteq obtained the CTI start-up label. The company focuses on development of novel coronary stents. It is funded by a group of private investors. The company’s development projects were/are supported by Swiss Government KTI/CTI grants.